- Nasdaq‑listed Wellgistics files S‑1 to integrate XRP and the XRP Ledger (XRPL) throughout its payment and treasury stack :
- US$50 million equity line from LDA Capital will finance XRPL infrastructure and strategic token purchases
Inside the Filing: From Supply‑Chain Settlements to Balance‑Sheet Strategy
Submitted on July 25, Wellgistics Health’s S‑1 registration statement lays out an ambitious plan to
weave Ripple’s technology through every layer of its business.
The healthcare logistics firm, whose network reaches roughly 6 000 pharmacies and 150 drug manufacturers, will deploy the XRP Ledger for real‑time B2B invoicing, rebate automation and cross‑border vendor payouts at a fractional cost compared with ACH or SWIFT rails.
Beyond day‑to‑day settlement, the company intends to treat XRP as a multi‑purpose corporate asset: a liquidity
reserve, a pledgeable collateral base for working‑capital credit lines and a yield‑bearing instrument via
on‑chain staking once U.S. rules permit. Management disclosed that tranches from the US$50 million
LDA Capital facility
“will be drawn explicitly to acquire XRP and to fund middleware linking our ERP stack to
XRPL smart contracts.”
The blueprint has been hailed by crypto attorney Bill Morgan as “more than just a treasury dabble”—a full‑stack
deployment that could set a template for other low‑margin industries seeking faster cash cycles.
Market Ripples, Regulatory Cross‑Currents and Diverging Opinions
XRP traded at about US$3.16 on Saturday afternoon, easing from a mid‑week spike to US$3.56 yet still up
sharply on the year. Traders attributed the rally to the Wellgistics news, the July 15 debut of ProShares’ leveraged Ultra XRP ETF (ticker: UXRP), and growing speculation that the Securities and Exchange Commission will eventually approve a spot XRP fund.
The SEC has already opened proceedings on Cboe BZX’s proposal to list the Franklin XRP ETF, with the next
decision window falling in mid‑August. A green light would supply a regulated liquidity sink that Wellgistics—and any other corporate accumulator—could tap for large‑scale purchases without roiling the underlying market.
Not everyone is convinced. Securities lawyers have questioned the optics of a healthcare distributor amassing
a sizable crypto treasury while still pre‑revenue, warning that volatility could complicate financial
reporting; others see the move as investor marketing masquerading as innovation.
For now, however, the filing has breathed fresh life into a long‑running debate over whether XRP’s
real‑world utility can translate into durable market value.
